Randomized Sham-controlled Trial of Targeted Lung Denervation in Patients with Chronic Obstructive Pulmonary Disease (AIRFLOW-3)

作者：Pallav L. Shah, Dirk‐Jan Slebos, Richard Sue, Surya P. Bhatt, Christian Ghattas, Charlie Strange, Bruno Degano, Arschang Valipour, Stephan Eisenmann, José de Vinatea de Cárdenas, Charles‐Hugo Marquette, Jose Soto-Soto, Frank C. Sciurba, Francesca Conway, James Tonkin, Anand Tana, Nathaniel Marchetti, Jorine E. Hartman, Valentin Héluain, Nicolas Guibert, Gerard J. Criner · 发表于：American Journal of Respiratory and Critical Care Medicine · 年份：2025 · DOI：10.1164/rccm.202502-0404oc · 被引用次数：3 · 研究领域：Chronic Obstructive Pulmonary Disease (COPD) Research、Respiratory Support and Mechanisms

Abstract Rationale AIRFLOW-3 was a 1:1 randomized, double-blind, sham-controlled trial of the D’Nerva targeted lung denervation (TLD) system in patients with chronic obstructive pulmonary disease (COPD). Objective To evaluate the impact of TLD on COPD exacerbations compared with optimal medical treatment. Methods AIRFLOW-3 patients were symptomatic (COPD Assessment Test score ≥10) with moderate to very severe airflow obstruction (FEV1 ≥25% but ≤80% predicted) and Global Initiative for Chronic Obstructive Lung Disease E status (at least two moderate or one severe exacerbation during the previous 12 mo). The primary endpoint was a comparison of time to the first moderate or severe COPD exacerbation through 12 months between the treatment (TLD plus optimal medical treatment) and sham control groups (sham procedure plus optimal medical treatment). Secondary endpoints included the rate of severe COPD exacerbations, change in quality of life (St. George’s Respiratory Questionnaire for COPD and Short Form–36 questionnaire), change in lung function (FVC, FEV1, residual volume), and change in COPD Assessment Test score. Measurements and Main Results 388 patients were randomized at a 1:1 ratio at 32 sites. There was no difference between treatment and the sham procedure in terms of the probability of participants having a moderate or severe COPD exacerbation (hazard ratio, 1.268; 95% confidence interval, 0.988–1.628). At 1 year, the TLD group had less dyspnea (>1-point improveme...